SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Ribonucleic acid strands consisting of nucleotides important for protein bio-synthesis - 3d illustration
Drug Development
RNA Editing Hits the Clinic, Fueling New Hope for Rare and Common Diseases
With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery breakthroughs are needed to propel RNA editing to the next stage.
February 24, 2025
 · 
6 min read
 · 
Heather McKenzie
Pictured: bluebird bio logo on wall/device, courtesy of Pavlo Gonchar
Mergers & acquisitions
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M
The proposed acquisition by global investment firms Carlyle and SK Capital Partners could net shareholders $3 per share plus potential CVR dollars and provide bluebird bio with primary capital to expand the commercial reach of its gene therapies.
February 21, 2025
 · 
3 min read
 · 
Heather McKenzie
Digital collage modern art. Hands reaching together and shaking, with loading icon
Mergers & acquisitions
Concentra Offers to Buy Acelyrin, Endangering Proposed Merger With Alumis
Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding the combined company over until 2027.
February 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Signage at Pfizer's world headquarters in New York City
Gene therapy
Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
February 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Photo of a GLP-1 injector pen on a blue background
GLP-1s
Coalition Urges FDA to Act as Report Finds Illegal GLP-1 Ingredients ‘Flooding’ Into US
Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis. Separately, a group of state attorneys general has raised concerns about the unsafe GLP-1 drugs finding their way to American consumers.
February 21, 2025
 · 
4 min read
 · 
Tristan Manalac
Pictured: Front view of the CDC museum in Georgia
Vaccines
CDC Vaccine Advisory Board Meeting Postponed Days After RFK Jr. Confirmation
The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human Services, despite controversy regarding his anti-vaccine history.
February 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover key topics for the lobbying group, including the Inflation Reduction Act.
February 20, 2025
 · 
2 min read
 · 
Kate Goodwin
Financial and economic improvement, rapid growth in income and wages, profitable investment of funds, increase in investment portfolio and savings, man overcomes cliff with the help of a dollar sign.
Earnings
BridgeBio Stock Hits 1-Year High as Attruby Rx Numbers Double
BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to beat a 2025 sales consensus of $86 million.
February 20, 2025
 · 
2 min read
 · 
Annalee Armstrong
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
FDA
FDA Reels From ‘Indiscriminate’ Job Cuts Under Trump as Biopharma Appeals for Clarity
Morale is low at the FDA, which was hit with layoffs this week following RFK Jr.’s confirmation. Biopharma leaders and agency insiders fear further workforce cuts could delay new medicines.
February 20, 2025
 · 
5 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS